Edition:
United States

Amicus Therapeutics Inc (FOLD.OQ)

FOLD.OQ on NASDAQ Stock Exchange Global Market

12.31USD
18 Jan 2019
Change (% chg)

$0.01 (+0.08%)
Prev Close
$12.30
Open
$12.34
Day's High
$12.47
Day's Low
$12.05
Volume
636,642
Avg. Vol
883,815
52-wk High
$17.60
52-wk Low
$8.28

Latest Key Developments (Source: Significant Developments)

Amicus Therapeutics Says Daphne Quimi Promoted To Chief Financial Officer
Wednesday, 19 Dec 2018 04:01pm EST 

Dec 19 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS ANNOUNCES EXECUTIVE TEAM UPDATES.AMICUS THERAPEUTICS INC - DAPHNE QUIMI PROMOTED TO CHIEF FINANCIAL OFFICER.AMICUS THERAPEUTICS INC - DAPHNE QUIMI SUCCEEDS CHIP BAIRD.  Full Article

Amicus Therapeutics Inc And Certain Subsidiaries Entered Into Loan Agreement
Tuesday, 25 Sep 2018 08:28am EDT 

Sept 25 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS INC - ON SEPT 19, CO, CERTAIN SUBSIDIARIES, ENTERED INTO A LOAN AGREEMENT - SEC FILING.AMICUS THERAPEUTICS INC - LOAN AGREEMENT PROVIDES FOR A $150 MILLION SENIOR SECURED TERM LOAN TO BE EXTENDED TO AMICUS ON OR ABOUT CLOSING DATE.AMICUS THERAPEUTICS INC - TERM LOAN MATURES FIVE YEARS FROM DATE OF FIRST CREDIT EXTENSION.  Full Article

Amicus Therapeutics Reports Q2 Loss Per Share Of $0.33
Tuesday, 7 Aug 2018 07:00am EDT 

Aug 7 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND CORPORATE UPDATES.Q2 LOSS PER SHARE $0.33.Q2 REVENUE $21.3 MILLION VERSUS I/B/E/S VIEW $19.2 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.33 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 GALAFOLD REVENUE $80 MILLION TO $90 MILLION.UPDATING ITS FULL-YEAR 2018 NET CASH SPEND TO $220 TO $250 MILLION.  Full Article

Amicus Therapeutics Expects 2018 Net Cash Spend Of $230 Mln To $260 Mln
Monday, 8 Jan 2018 07:30am EST 

Jan 8 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS PROVIDES FULL-YEAR 2018 STRATEGIC OUTLOOK AND FINANCIAL GUIDANCE.AMICUS THERAPEUTICS SEES GALAFOLD FY 2018 REVENUE $75 MILLION TO $85 MILLION.CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES TOTALED ABOUT $359 MILLION AT DEC 31, 2017.EXPECTS FULL-YEAR 2018 NET CASH SPEND OF BETWEEN $230 MILLION AND $260 MILLION.CURRENT CASH POSITION IS ANTICIPATED TO FUND ONGOING OPERATIONS INTO AT LEAST SECOND HALF OF 2019.FY2018 REVENUE VIEW $88.9 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Amicus Therapeutics Submits New Drug Application To U.S. FDA For Migalastat
Thursday, 14 Dec 2017 07:30am EST 

Dec 14 (Reuters) - Amicus Therapeutics Inc ::AMICUS THERAPEUTICS SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR MIGALASTAT FOR TREATMENT OF FABRY DISEASE.AMICUS THERAPEUTICS INC - ‍LOOK FORWARD TO POTENTIAL U.S. APPROVAL OF MIGALASTAT IN 2018​.  Full Article

Amicus Therapeutics Q3 loss per share $0.69
Wednesday, 8 Nov 2017 07:00am EST 

Nov 8 (Reuters) - Amicus Therapeutics Inc ::Amicus therapeutics announces third quarter 2017 financial results and corporate updates.Q3 loss per share $0.69.Q3 revenue $10.9 million versus I/B/E/S view $9.5 million.Q3 adjusted loss per share $0.41 excluding items.Q3 earnings per share view $-0.31 -- Thomson Reuters I/B/E/S.Amicus Therapeutics Inc - ‍reiterated full-year 2017 financial guidance​.Amicus Therapeutics Inc - ‍current cash position anticipated to fund ongoing operations into at least H2 2019​.  Full Article

Vanguard Group reports 5.85 percent passive stake in Amicus Therapeutics as of December 31, 2016
Thursday, 9 Feb 2017 12:07pm EST 

Vanguard Group Inc :Vanguard Group Inc reports a 5.85 percent passive stake in Amicus Therapeutics Inc as of December 31, 2016 -SEC filing.  Full Article

Photo

Amicus sets $315,000 price for new Fabry disease treatment

Amicus Therapeutics on Monday set an average price of $315,000 per year for its newly approved Fabry disease treatment, a price it believes is below that of the main existing treatment in the United States.